FDA undoes Astellas’ bid for fast review of menopause drug

Shares in Astellas Pharma were weaker this morning on the news that the FDA has delayed its review of one of its top pipeline prospects – menopause drug fezolinetant – by

Bayer extends elinzanetant trials to include breast cancer

Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast ca

Astellas files menopause drug fezolinetant in US, setting up...

Astellas remains on course to be the first drugmaker to bring a new non-hormonal therapy for symptoms of menopause to market, after the FDA started a review of its orally-active neurokinin-

Astellas' eyes filings for menopause drug fezolinetant after...

Astellas looks to be in pole position to bring a new non-hormonal therapy for symptoms of menopause to market, after its candidate fezolinetant cleared a phase 3 safety study.

Astellas pushes non-hormonal menopause drug into phase 3